Tag Archives: Vytorin

Merck/Schering-Plough Merger Highlights (Update 1)

By George Koroneos | Published: March 9, 2009
Merck and Schering-Plough’s CEOs are giving a run down of the benefits of the $41.1 billion merger, announced this morning, in a conference call with investors. Here are some of the highlights: • Total price of the sale will be $41.1 billion or $23.6 per Schering share. • This deal is structured as a reverse merger with [...]
Posted in Deals, Strategy | Also tagged , , , , , | 4 Comments

Schering-Plough to Merge with Merck for $41.1 Billion

By George Koroneos | Published: March 9, 2009
Merck’s Richard T. Clark Image via Wikipedia Merck announced, a little over an hour ago, that it had signed an agreement with Schering-Plough’s board of directors to merge the two companies under the Merck name. The stock and cash transaction is worth over $41 billion with Schering shareholders receiving $10.50 per share in cash and 0.5767 of a [...]
Posted in Deals | Also tagged , , , , | Leave a comment

FDA Declares: Keep Taking Your Vytorin

By George Koroneos | Published: January 9, 2009
It’s official. Vytorin (ezetimibe/simvastatin) still does what it’s supposed to do—significantly decrease LDL cholesterol. FDA, yesterday, released its assessment of the now-notorious ENHANCE trial—which tested whether Vytorin was better than simvastatin alone in reducing arterial plaque in a group of patients with severe genetic high cholesterol. It wasn’t, and publication of the study set off a [...]
Posted in Regulatory | Also tagged , , , , , | Leave a comment

Merck to Axe 7,200 Positions

By George Koroneos | Published: October 22, 2008
Not much in the way of good news at Merck this morning. The pharma giant announced that it is revising its financial guidelines through 2010, and eliminating 7,200 positions by 2011. The move is expected to save the company $3.8 billion to $4.2 billion through 2013. The layoffs will be staggered throughout different parts of the [...]
Posted in Sales, Strategy | Also tagged , , , , , | Leave a comment